PCN93 Endocrine Therapyadherence and Persistence and Survival Among Women With Breast Cancer in Brazil  by Brito, C. et al.
vided 0.30 and Docetaxel 0.31. Therefore, Erlotinib therapy is positioned as a dom-
inant (more effective and less costly) compared to Docetaxel and Pemetrexed.
These results were consistent in the sensitivity analysis, giving strength to them.
Therefore, Erlotinib could represent annual savings of $5860 compared to Do-
cetaxel and $7090 with Pemetrexed per patient. Additionally, Erlotinib contributes
to costs reduction in patients with NSCLC, because it is a chemotherpay adminis-
tered orally, instead os a intravenous infusion, andwith a better safety profilewithno
hematologic toxicity in comparison with standard chemotherapy. CONCLUSIONS:
The cost-utility analysis of the use of Erlotinib vs. Docetaxel or Pemetrexed in the
treatment of previously treated metastatic or advanced NSCLC showed that Erlo-
tinib is a cost-effective therapy because it consumes fewer resources to obtain
clinical success. Under the perspective of the Mexican public health system Erlo-
tinib is dominant alternative in second-line treatment for patients with advanced
or metastatic NSCLC.
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OBJECTIVES: Cancer is the second leading cause of death in the Slovak Republic
with 23 000 new cases diagnosed every year and highest incidence in age group
over 60. Antineoplastic agents prevent or inhibit the maturation and proliferation
of neoplasms. Themain objective of this studywas to evaluate the consumption of
antineoplastic agents in Slovak Republic within the period of 2008-2011.
METHODS: Analysed data were abstracted from the Slovak Institute of Drug Con-
trol and provided by wholesalers due to their legal obligation towards the SIDC.
Processed informations include the number of medicine packages and financial
expenditures. RESULTS: There was a gradual rise in antineoplastic agents utilisa-
tion in terms of financial expenditures from 98 605 418 € in 2009 to 105 786 256 € in
2011. Third quartal of 2010 was hitting a peak with 27 261 629 € respectively while
the first quartal plummeted to 23 307 249 €, which presents the lowest performance
within followed period. Number of packages rose sequentially from 513 193 in 2008
to 593 067 in 2011. Average price per package was fluctuating from 168 € in 2010 to
192 € in 2008. Highest financial declinewas observed in group of plant alkaloids and
other natural products ( from 12 977 717 € in 2008 to 6 840 618 € in 2011). Most
significant expeditures increase from the group of antineoplastic agents reached
capecitabinewith 3 491 954 € in 2008 and 4 560 623 € in 2011. Its number of packages
almost doubled from 8 725 in 2008 to 14 145 in 2011. CONCLUSIONS: The slight rise
in consumption of antineoplastic agents is caused by higher incidence and preva-
lence and better diagnose of cancer disease in Slovak population. Higher use of
capecitabine can be interpretted in pursuance of breast and colorectal cancer oc-
curence.
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OBJECTIVES: Innovative pharmaceutical treatments contribute significant value
for improving and extending the lives of cancer patients. Many innovative oncol-
ogy products become standard of care and continue to produce significant value
well beyond the period of innovator exclusivity. Current tools used to guide 3rd
party funding decisions are made at the beginning of product lifecycles and fail to
account for the long-term stream of value, particularly from acquisition cost re-
duction after innovator exclusivity. The objective of this study was to propose a
framework to highlight this important aspect for determining the value of new
drug innovation using two case studies. METHODS: The drugs selected for the
cases studies were paclitaxel and azacitidine. Pharmacoeconomic studies evaluat-
ing these agents were identified. Applying off-patent prices after exclusivity, a
lifecycle ICER was determined by annually amortizing the ICER value over the
potential useful life of a product. Results are in Canadian dollars. RESULTS: Pacli-
taxel remains a standard of care in advanced ovarian and breast cancer even after
innovator loss of exclusivity in 2004. Using the current off-patent price, the lifecycle
ICER for paclitaxel is estimated to be approximately $26,000 per QALY. Azacitidine
has become the standard of care for higher-risk MDS in Canada. It is anticipated
that azacitidine will remain part of standard care beyond innovator exclusivity.
Assuming a 25% reduction in acquisition cost and a further 10 year useful life, the
lifecycle ICER for azacitidine is estimated to be approximately $36,000 per QALY.
CONCLUSIONS: Many innovative oncology medicines provide significant societal
value well past the period of innovator exclusivity. Current approaches for assess-
ing economic value fail to recognize this unique aspect and may be undervaluing
new oncology medicines. Therefore, approaches should evolve to better account
for the societal value a product produces over its useful life span.
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OBJECTIVES: Identify explanatory variables of hormone therapy (HT) adherence
and persistence (A&P) in women with breast cancer (BC), and evaluating the effect
of such variables in BC survival rates. METHODS: Retrospective longitudinal data
from a cohort of 5861 women with BC, submitted to HT, was put together through
linkage of the Brazilian National Cancer Institute datasets, including the control of
medicines delivered at its Pharmacy. A logistic regression model was applied to
study adherence. Cox proportional hazard models were used to estimate persis-
tence and BC survival. RESULTS: The proportion of treatment adherent was 75.3%.
At the end of the first and the fifth year of treatment, respectively, overall persis-
tence to treatment was 79% and 31%, and survival was 94% and 71%. Similarly,
better A&P to treatment, as well as BC survival, were associated with higher edu-
cation, having a partner, lower cancer stages, being submitted to surgery, having
less inpatient care, making outpatient visits to a Mastologist and a Clinical Oncol-
ogist, and the need of less exams. Older women were more likely to adhere and to
persist to treatment, but those aged 70 years old or more presented higher hazard
of death. Alcoholism and tobacco use was associated with lower A&P. Longer time
between diagnosis and the beginning of HT and cancer family historywere, respec-
tively, a risk and a protective factor to treatment persistence and survival. Psycho-
therapy was protective for adherence and survival. Finally, treatment adherence
was positively associated with BC survival, being combined tamoxifen and aroma-
tase inhibitor explicative of lower adherence, while only aromatase inhibitor use
was associated with higher hazard of death. CONCLUSIONS: In this cohort, of
the patients did not adhere, only 31% completed the 5-year hormone treatment,
and 71% were alive after five years. Socio-demographic, behavioral, clinical and
health care aspects explained partially variations in these dependent variables.
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OBJECTIVES: Since the launch of Imatinib, the survival of chronic myeloid leuke-
mia (CML) has significantly improved, but also caused enormous increase in long-
termcosts of CML care. Neither health-related utility of CMLpatients nor long-term
cost-effectiveness of imatinib, however, has been investigated in Taiwan. This
feasibility study aims to explore the applicableness of time-trade-off (TTO) tomea-
sure utility of CML patients treated with imatinib.METHODS: This cross-sectional
study was conducted at a medical center in southern Taiwan from June 2011 to
January 2012. Outpatients with defined diagnosis of CML and receiving imatinib
were invited to participate. After TTO measurement, semi-structure interviews
were conducted to explore participates’ perceptions. The interviews were audio-
taped, transcribed verbatim and analyzed by constant comparison untill
saturation. RESULTS: Of all, 22 (mean age: 52.415.83 years, male: 63.6%) of the 24
participants completed the study. The average utility was 0.7740.219. Most par-
ticipants accepted current health status and life expectancy, and considered cur-
rent health status is not different from ideal situation. Mid-age participants traded
off life span with parenting duty, while the elderly considered companion time
with their partners. For those who chose shorter life span with better health, the
main concern was financial burden to family because the disease-related fatigue
constrained activity and work ability. In addition, regular medical treatment was
also considered by those who desired better career paths, long-term traveling and
those consisting ofmulti-comorbidity. Moreover, uncertainty about future, limited
social support and financial difficulty were also the reasons for trading off.
CONCLUSIONS: TTO is applicable to measure utility for CML patients. Participants
receiving imatinib generally presented satisfactory health status and trading re-
maining years of lifewith other concerns. To validate this tool, further studies need
to explore utilities of patients with disease symptoms or drug-related side effects,
and compare the results with disease-specific measures.
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OBJECTIVES: The limitations of generic preference-based measures in disease ar-
eas such as oncology are widely recognised. Condition-specific measures offer
more relevant assessments of health and can be used to derive utilities. The aim of
this study was to use data collected with the European Organization for Research
and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer (QLQ-
C30) in a myelofibrosis clinical trial to derive utilities. METHODS: QLQ-C30 data
were collected over 48 weeks in an open-label trial of ruxolitinib (n146) versus
best-available therapy (BAT) (n73). Two algorithms were used to map QLQ-C30
scores to utilities: the first mapped to EQ-5D utilities, the second to condition-
specific preference weights using a QLQ-C30 item subset (EORTC-8D). Changes
from baseline (CFB) in utilities were calculated by treatment at week 48. Mean
utilities by presence of constitutional symptoms (CS) (weight loss, fever or night
sweats) and response (35% reduction in spleen volume from baseline) were also
derived. RESULTS:Mean (SE) utility CFB from the EQ-5D algorithmwas 0.082 (0.025)
for ruxolitinib and 0.012 (0.040) for BAT. From the EORTC-8D algorithm, mean (SE)
CFB was 0.038 (0.013) for ruxolitinib and 0.013 (0.021) for BAT. Patients without CS
had highermean (SE) utilities than patientswith CS using both algorithms—EQ-5D,
0.730 (0.017) without and 0.539 (0.031) with CS; EORTC-8D, 0.818 (0.009) without and
0.719 (0.016) with CS. Similarly, patients defined as responders had higher mean
(SE) utilities than nonresponders using both algorithms—EQ-5D, 0.754 (0.029) for
responders and 0.670 (0.024) for nonresponders; EORTC-8D, 0.843 (0.015) for re-
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